Intraplacental coagulation in intrauterine growth restriction: Cause or result?

Seminars in Thrombosis and Hemostasis

Volumn 27, Issue 2, 2001, Pages 107-114

  Sugimura, Motoi ^a   Ohashi, Ryouta ^a   Kobayashi, Takao ^a   Kanayama, Naohiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coagulation; Hypercoagulability; Intrauterine growth restriction; Placental circulation; Thrombosis

Indexed keywords

ARTICLE; FIBRIN DEPOSITION; HISTOPATHOLOGY; HUMAN; HYPERCOAGULABILITY; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; PLACENTA CIRCULATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PLACENTAL CIRCULATION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOSIS;

EID: 0035025249     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-14068     Document Type: Article

References (40)

1. 1. Kramer MS, Olivier M, McLean FH, Willis DM, Usher RH. Impact of intrauterine growth retardation and body proportionality on fetal and neonatal outcome. Pediatrics 1990;86: 707-713
2. 2. Chard T, Yoong A, Macintosh M. The myth of fetal growth retardation at term. Br J Obstet Gynaecol 1993;100: 1076-1081
3. 3. Martyn CN, Gale CR, Sayer AA, Fall C. Growth in utero and cognitive function in adult life: follow-up study of people born between 1920 and 1943. BMJ 1996;312:1393-1396
4. 4. Minior VK, Divon MVK. Fetal growth restriction at term: myth or reality? Obstet Gynecol 1998;92:57-60
5. 5. Fox H, Elston CW. Pathology of the placenta. In: Bennington JL, ed. The Placenta in Abnormalities and Disorders of the Fetus. London: WB Saunders; 1978:248-251
6. 6. Wentworth P. The incidence and significance of intervillous thrombi in the human placenta. J Obstet Gynaecol Br Commonw 1964;71:894-898
7. 7. Naeye RL. Fetal growth. In: Naeye RL, Tafari N, eds. Risk Factors in Pregnancy and Diseases of the Fetus and Newborn. Baltimore: Williams & Wilkins; 1983:19-75
8. 8. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathological features. Am J Obstet Gynecol 1995;173: 1049-1057
9. 9. Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL. Fibrin-mediated vascular injury. Am J Pathol 1984;117:418-428
10. 10. Harris EN, Gharavi AE, Hughes GRV. Anti-phospholipid antibodies. Clin Rheum Dis 1985;11:591-609
11. 11. Sheppard, BL, Burk G, Bonnar J. Platelet activation in normotensive and hypertensive pregnancies complicated by intrauterine growth retardation. Br J Obstet Gynaecol 1994; 101:209-214
12. 12. Sugimura M, Su F, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Anticoagulant activity in non-immunoglobulin fraction from plasma of patients with antiphospholipid syndrome. Semin Thromb Hemost 1998;24:473-477
13. 13. Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996:88:3456-3464
14. 14. Abdul Halim MB, Kanayama N, Maradny EE, et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in pre-eclampsia and eclampsia: their significances. Am J Obstet Gynecol 1996;174:272-277
15. 15. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-167
16. 16. Lim KH, Zhou Y, Janatpour M, et al. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 1997;151:1809-1818
17. 17. Lyall E, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996;1:107-116
18. 18. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991:66;24302-24307
19. 19. Kumar R, Béguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 1995;74:962-968
20. 20. Kinlough-Rathbone RL, Perry DW. Prolonged expression of procoagulant activity of human platelets degranulated by thrombin. Thromb Haemost 1995;74:958-961
21. 21. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134:1087-1097
22. 22. Vogt E, Ng AK, Rote NS. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Am J Obstet Gynecol 1996;174:700-707
23. 23. Sugimura M, Kobayashi T, Shu F, Kanayama N, Terao T. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice. Placenta 1999;20:555-560
24. 24. Rand JH, Wu X-X, Guller S, et al. Reduction of annexin-V (placental anticoagulant protein) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994;171:1566-1572
25. 25. Shu F, Sugimura M, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest 2000;49:17-23
26. 26. Funakoshi T, Heimark R, Hendrickson LE, MacMullen BA, Fujikawa K. Human placental anticoagulant protein: isolation and characterization. Biochemistry 1987;26:5572-5578
27. 27. Andree HAM, Stuart MCA, Hermens WT, et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992;267:17907-17912
28. 28. Sugimura M, Donato R, Kakkar VV, Scully MF. Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagul Fibrinolysis 1994;5:365-373
29. 29. Maki M, Shidara Y, Sato H. Placental annexin V isolation. Characterization and possible functions. In: Moss SE, ed. The Annexins. London: Portland Press; 1992:153-164
30. 30. Sato Y. Distribution and motion of calphobindin in the human body. Acta Obstet Gynaecol Jpn 1991;43:65-72
31. 31. Krikun G, Lockwood CJ, Wu X-X, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994;15;601-612
32. 32. Rand JH, Wu X-X, Andree HAM, et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med 1997;337:154-160
33. 33. Schroit AJ, Madsen JW, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 1985;260:5131-5138
34. 34. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler I. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991;51: 3062-3066
35. 35. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995;182:1597-1601
36. 36. Nayar R, Lage JM. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome: a case report and review of the literature. Hum Pathol 1996;27:201-206
37. 37. Nishihira J. Reevaluation of the biological functions of macrophage migration inhibitory factor (MIF) within and beyond the immune system. Recent Res Dev Immunol 1999;1: 95-111
38. 38. Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira J. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophage in autocrine and paracrine fashion. Immunology 1997;92:131-137
39. 39. Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991;337:1427-1431.
40. 40. Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314: 253-257